Relay Therapeutics (RLAY) Osake Kurssi

Relay Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Relay Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, Inc., Beam Therapeutics Inc., and Nurix Therapeutics Inc.

Relay Therapeutics Inc. is a biotechnology company that focuses on discovering and developing new medicines to potentially treat cancer and other diseases. Founded in 2016, Relay Therapeutics combines the fields of computation and experimental biology to design innovative therapies. The company's platform integrates advanced technology, including artificial intelligence and machine learning, to gain a deeper understanding of protein motion and its role in diseases. By leveraging this expertise, Relay Therapeutics aims to discover drugs that can effectively target specific proteins and improve patient outcomes. With its commitment to scientific excellence and cutting-edge research, Relay Therapeutics is dedicated to revolutionizing the field of drug discovery.

Relay Therapeutics Inc has achieved several significant milestones since its inception. This biotechnology company has successfully built a proprietary drug discovery platform that combines computation and experimental approaches to design new small molecule therapies. In 2020, Relay Therapeutics raised approximately $400 million in its initial public offering (IPO), indicating strong market interest in its innovative capabilities. Furthermore, the company has established strategic collaborations with renowned organizations like Genentech and Eli Lilly to accelerate the development of potential breakthrough medicines. These achievements highlight Relay Therapeutics Inc's commitment to revolutionize drug discovery through its cutting-edge platform and strategic partnerships.

Relay Therapeutics Inc is primarily present in the United States.

Relay Therapeutics Inc represents the values of innovation, collaboration, and patient-centricity. The company's corporate philosophy is centered around leveraging the power of protein motion to discover new medicines for patients. Relay Therapeutics is committed to fostering a culture of inclusivity and diversity, empowering its employees to think creatively and work collaboratively towards its mission. By combining cutting-edge technology and deep expertise in structural biology, the company strives to unlock novel insights into protein motion and develop transformative therapies. Relay Therapeutics Inc is dedicated to improving the lives of patients by translating scientific discoveries into impactful medicines.

Analyytikot asettavat tällä hetkellä Relay Therapeutics-osakkeelle keskimääräisen tavoitehinnan 26,13 USD (mediaani: 27,00 USD), mikä merkitsee +48,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.

Relay Therapeutics Analyytikkojen kursstavoitteet 2026

20 analyytikkoa arvioi tällä hetkellä Relay Therapeutics-osaketta: 19 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Relay Therapeutics-yhtiöltä 11,16 M USD liikevaihtoa ja −1,33 USD osakekohtaista tulosta.

Relay Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Relay Therapeutics-osake noteerataan hintaan 15,77 EUR (17,66 USD).

Relay Therapeutics-osake (RLAY) on listattuna 1 pörssissä, muun muassa: NASDAQ (RLAY).

Relay Therapeutics is an innovative biotechnology company focused on the discovery and development of new drugs for serious diseases. The company was founded in 2016 and uses a unique computer-based approach to identify new targets for drugs. The company concentrates on developing drugs for diseases that currently lack effective treatments. It employs a computer-based approach to identify new targets for drugs. Relay Therapeutics has developed an innovative technology platform that combines synthetic chemistry and modern biology. Relay Therapeutics offers a wide range of products and services to its customers. The company utilizes a dynamic and customer-centric business strategy, ensuring that it meets the needs of its customers while remaining innovative. Collaborating with other companies and institutions to leverage its technology and expertise and develop innovative products and services is a crucial component of Relay Therapeutics' business model. The company partners with other companies and universities to develop innovative drugs and diagnostic procedures. Relay Therapeutics has already established successful partnerships with major pharmaceutical companies such as Sanofi and Vertex Pharmaceuticals, as well as other industry leaders. Relay Therapeutics has built a strong pipeline of projects focusing on the development of new drugs. Its research programs concentrate on developing drugs for cancer, neurodegenerative diseases, and rare diseases. Furthermore, Relay Therapeutics also relies on strategic partnerships to expand its product pipeline and enter new markets. The company has already established successful partnerships with major pharmaceutical companies such as Sanofi and Vertex Pharmaceuticals, as well as other industry leaders. The business model of Relay Therapeutics is based on the following key components: - Utilization of technology platforms: Relay Therapeutics utilizes state-of-the-art computer-based technology platforms to identify new targets for drugs. - Focus on serious diseases: Relay Therapeutics focuses on developing drugs for serious diseases that currently lack effective treatments. - Collaboration with other companies and institutions: Relay Therapeutics collaborates with other companies and institutions to leverage its technology and expertise in developing innovative products and services together. - Wide range of products and services: Relay Therapeutics offers a wide range of products and services tailored to the needs of its customers. Overall, Relay Therapeutics employs a collaborative business strategy to develop innovative drugs for serious diseases. With its technology platforms, research programs, and strategic partnerships, the company has gained a strong position in the biotechnology industry and is well-positioned to continue developing innovative solutions for the healthcare sector.

odotettu liikevaihto Relay Therapeutics on 11,16 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Relay Therapeutics on −228,81 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Relay Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −13,24. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Relay Therapeutics-osakkeen arvostusta.

Relay Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 271,45. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Relay Therapeutics-osakkeen arvostuskennuslukuna.

Relay Therapeutics:n Eulpool-laatuscore on 3/10.

Relay Therapeutics:n ISIN on US75943R1023. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Relay Therapeutics:n WKN on A2P9AA. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Relay Therapeutics:n ticker on RLAY. Tämä pörssinoteeraus käytetään Relay Therapeutics-osakkeiden kauppaan pörssissä.